Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

BACKGROUND: SARS-CoV-2 has caused millions of deaths, and, since Aug 11, 2020, 20 intramuscular COVID-19 vaccines have been approved for use. We aimed to evaluate the safety and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shipo, Huang, Jianying, Zhang, Zhe, Wu, Jianyuan, Zhang, Jinlong, Hu, Hanning, Zhu, Tao, Zhang, Jun, Luo, Lin, Fan, Pengfei, Wang, Busen, Chen, Chang, Chen, Yi, Song, Xiaohong, Wang, Yudong, Si, Weixue, Sun, Tianjian, Wang, Xinghuan, Hou, Lihua, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313090/
https://www.ncbi.nlm.nih.gov/pubmed/34324836
http://dx.doi.org/10.1016/S1473-3099(21)00396-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313090/
https://www.ncbi.nlm.nih.gov/pubmed/34324836
http://dx.doi.org/10.1016/S1473-3099(21)00396-0

Ejemplares similares